Founded in 1973, USA-based medical device manufacturer DeRoyal is committed to improving both the clinical quality and economic health of its customers. With 2,000 employees, 2.5 million square feet (232,000 square meters) under roof, operations in six countries and six U.S.A. states and manufacturing assets on three continents, DeRoyal brings value to its customers in several distinct markets; these include surgical devices, unitized delivery systems, orthopedic supports & bracing and wound care dressings. Key core competencies include injection molding, device assembly, metal fabrication, converting, electronics assembly as well as sterilization services. DeRoyal combines these fundamental manufacturing capabilities with its own unique services and information technology tools to deliver unparalleled value to its customers with a particular expertise in disrupting dysfunctional markets.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

DECK 7 OPTIMIZES ITS STRATEGIC MARKETING FOR 2020 USING A REVISED ABM STRATEGY

PR.com | February 04, 2020

news image

Being one of the best lead-gen service providers in San Diego, California, DECK 7 is more data-focused than ever. The brand has optimized its strategic marketing approach by scaling ABM in a number of effective ways. By combining its time-tested ABM framework with a strong data-driven approach, DECK 7 is empowering numerous brands in maximizing growth and driving actionable results. DECK 7’s ABM prowess is defined by its skilled team members and their advanced approach to B2B marketing. Th...

Read More

MEDICAL

SELFDECODE OFFERS FREE KIDNEY HEALTH DNA REPORT TO CELEBRATE NATIONAL KIDNEY MONTH

SELFDECODE | March 07, 2022

news image

SelfDecode is kicking off National Kidney Month with a national campaign to raise awareness about the importance of preventative measures to optimize kidney health. For the month of March, SelfDecode is offering a free Kidney Health DNA Report to anyone who uploads a DNA file for analysis. Through genetic testing, SelfDecode is providing people with the opportunity to gain insight regarding their genetic predisposition for health issues and receive personalized recommendations to ...

Read More

MEDICAL

ALLIGATOR BIOSCIENCE ANNOUNCES IND APPROVAL FOR CD40 TARGETING ANTIBODY MITAZALIMAB

Alligator Bioscience | December 07, 2020

news image

Alligator Bioscience declares an affirmed IND (Investigational new Drug) for the CD40 targeting antibody mitazalimab. IND endorsement by the US Food and Drug Administration (FDA) is an essential to begin clinical preliminaries in the USA. As of late, new benchmark information was distributed indicating that mitazalimab can possibly be top tier in the CD40 field. The comparison demonstrated the potent immune-activating properties and anti-tumor effects of mitazalimab. "W...

Read More

BIOCLINICA ANNOUNCES THAT IT WILL LEVERAGE BIOCLINICA'S INTERACTIVE RESPONSE TECHNOLOGY (IRT) FOR THEIR EXIT COVID-19 STUDY

Bioclinica | September 10, 2020

news image

Bioclinica, an integrated solutions provider of clinical life science and technology expertise, delivering powerful insight into clinical trial development in bringing new therapies to people worldwide, announced today that Direct Biologics, a market leading innovator and science-based manufacturer of regenerative products, will leverage Bioclinica's Interactive Response Technology (IRT) for their EXIT COVID-19 study — a multi-center FDA phase II clinical trial for the use of ExoFlo&tr...

Read More
news image

DECK 7 OPTIMIZES ITS STRATEGIC MARKETING FOR 2020 USING A REVISED ABM STRATEGY

PR.com | February 04, 2020

Being one of the best lead-gen service providers in San Diego, California, DECK 7 is more data-focused than ever. The brand has optimized its strategic marketing approach by scaling ABM in a number of effective ways. By combining its time-tested ABM framework with a strong data-driven approach, DECK 7 is empowering numerous brands in maximizing growth and driving actionable results. DECK 7’s ABM prowess is defined by its skilled team members and their advanced approach to B2B marketing. Th...

Read More
news image

MEDICAL

SELFDECODE OFFERS FREE KIDNEY HEALTH DNA REPORT TO CELEBRATE NATIONAL KIDNEY MONTH

SELFDECODE | March 07, 2022

SelfDecode is kicking off National Kidney Month with a national campaign to raise awareness about the importance of preventative measures to optimize kidney health. For the month of March, SelfDecode is offering a free Kidney Health DNA Report to anyone who uploads a DNA file for analysis. Through genetic testing, SelfDecode is providing people with the opportunity to gain insight regarding their genetic predisposition for health issues and receive personalized recommendations to ...

Read More
news image

MEDICAL

ALLIGATOR BIOSCIENCE ANNOUNCES IND APPROVAL FOR CD40 TARGETING ANTIBODY MITAZALIMAB

Alligator Bioscience | December 07, 2020

Alligator Bioscience declares an affirmed IND (Investigational new Drug) for the CD40 targeting antibody mitazalimab. IND endorsement by the US Food and Drug Administration (FDA) is an essential to begin clinical preliminaries in the USA. As of late, new benchmark information was distributed indicating that mitazalimab can possibly be top tier in the CD40 field. The comparison demonstrated the potent immune-activating properties and anti-tumor effects of mitazalimab. "W...

Read More
news image

BIOCLINICA ANNOUNCES THAT IT WILL LEVERAGE BIOCLINICA'S INTERACTIVE RESPONSE TECHNOLOGY (IRT) FOR THEIR EXIT COVID-19 STUDY

Bioclinica | September 10, 2020

Bioclinica, an integrated solutions provider of clinical life science and technology expertise, delivering powerful insight into clinical trial development in bringing new therapies to people worldwide, announced today that Direct Biologics, a market leading innovator and science-based manufacturer of regenerative products, will leverage Bioclinica's Interactive Response Technology (IRT) for their EXIT COVID-19 study — a multi-center FDA phase II clinical trial for the use of ExoFlo&tr...

Read More